UPC CFI 437/2024

Vor dem UPC: GXD-Bio Corporation (8 Verfahren)·Myriad Genetics Group (8 Verfahren)

• 2025-12-19
  Counterclaim for revocationÖffentlich

  Zusammenfassung: The Munich Local Division dismissed both the infringement action (UPC_CFI_437/2024) brought by GXD-Bio Corporation and the counterclaim for revocation (UPC_CFI_681/2024) brought by the Myriad defendants, concerning EP 3 346 403 (a patent on data processing/gene expression analysis for identifying endogenous reference genes). The Court found no infringement because the accused products (Myriad test kits) did not use the claimed three-step normalization method — the products used a single-step average normalization that differed from the patented calculation method. The counterclaim for revocation was also dismissed, so the patent was maintained. Each party bears its own costs, with costs capped at EUR 600,000 total.

  Rechtsfragen anzeigen (5)

  • Direct and indirect patent infringement
  • Claim construction of normalization method
  • Timeliness of evidence under R. 9.2 RoP
  • Counterclaim for revocation
  • Patent amendment auxiliary requests